1249PCMET EXPRESSION AND ACTIVITY OF FIRST-LINE ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): EXPLORATORY ANALYSIS OF THE RANDOMIZED PHASE III TORCH TRIAL

1249PCMET EXPRESSION AND ACTIVITY OF FIRST-LINE ERLOTINIB IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS): EXPLORATORY ANALYSIS OF THE RANDOMIZED PHASE III TORCH TRIAL

Abstract Aim: In the TORCH trial, molecularly unselected pts with advanced NSCLC were randomized to erlotinib (E) or cisplatin + gemcitabine (CG) as first line within planned treatment sequences. Several biomarkers were studied with exploratory aim. Here we report cMET and PTEN data. Methods: cMET a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv438-iv438
Hauptverfasser: Tsao, M., Di Maio, M., Kim, L., Liu, G., Xu, J., Gebbia, V., Burgio, M.A., Alam, Z.Y., Valmadre, G., Higgins, B., Signoriello, S., Rossi, A., Leighl, N.B., Maione, P., Butts, C.A., Ciardiello, F., Feld, R., Gallo, C., Gridelli, C., Perrone, F.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Aim: In the TORCH trial, molecularly unselected pts with advanced NSCLC were randomized to erlotinib (E) or cisplatin + gemcitabine (CG) as first line within planned treatment sequences. Several biomarkers were studied with exploratory aim. Here we report cMET and PTEN data. Methods: cMET and PTEN immunohistochemistry (IHC) was performed using standard method and SP44 (Ventana) and 138G6 (Cell Signaling) antibodies, respectively. H-score (intensity x % stained tumor cells) was used to classify cMET IHC (
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdu349.28